Last reviewed · How we verify
Placebo (for pantoprazole)
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes. Used for Control arm in pantoprazole clinical trial (indication under investigation).
At a glance
| Generic name | Placebo (for pantoprazole) |
|---|---|
| Sponsor | McMaster University |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials. In this case, it serves as the comparator arm in a Phase 3 trial evaluating pantoprazole (a proton pump inhibitor). Any observed effects in the placebo group result from expectation, conditioning, and natural disease progression rather than direct molecular action.
Approved indications
- Control arm in pantoprazole clinical trial (indication under investigation)
Common side effects
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years (PHASE2)
- Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery (PHASE2)
- Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy (PHASE2)
- Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (PHASE4)
- Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease (PHASE4)
- Aspirin in Young Psychotic Patients (PHASE2, PHASE3)
- Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for pantoprazole) CI brief — competitive landscape report
- Placebo (for pantoprazole) updates RSS · CI watch RSS
- McMaster University portfolio CI